Schering PEG-Intron/Rebetol committee update
Executive Summary
FDA's Antiviral Drugs Advisory Committee will receive an update on the approval of Schering-Plough's PEG-Intron (peginterferon alfa-2b) for use alone or in combination with Rebetol (ribavirin) for treatment of hepatitis C at its Dec. 12 meeting. PEG-Intron was approved for combination therapy with Rebetol in August with certain postmarketing study commitments (1"The Pink Sheet" Aug. 20, p. 24). The meeting will begin at 8:15 a.m. at the Holiday Inn in Bethesda, Md...
You may also be interested in...
Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen
Schering-Plough will study alternative dosing regimens for PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin) following approval of the hepatitis C combination therapy.
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.